Heparin induced thrombocytopenia
Authors
Abstract:
Abstract Background and Objectives Heparin is still a commonly used anticoagulant in prophylaxis and treatment of thromboembolic events. Heparin-induced thrombocytopenia (HIT) is a life-threating adverse drug reaction of heparin. The diagnosis of HIT is made based on two important criteria, firstly clinical evaluation and secondly laboratory testing. In this comprehensive review, the authors will emphasize the risk factors, clinical presentation, pathophysiology, diagnostic principals and treatment of HIT. Materials and Methods Our study method was based on the search in the PubMed Database by related key words like: "heparin", "heparin induced thrombocytopenia", "pathophysiology", "diagnosis" and “treatment” published during 1997 to 2018. Results The disease is still a life-threatening event caused by the creation of an antibody against the heparin-PF4 complex and, if platelets are activated, can lead to thrombotic events in patients. Laboratory diagnostic methods are important in excluding or confirming the diagnosis of HIT, especially in patients who are moderate or highly clinical probability of HIT suspected. Conclusions Today, with a better understanding of the pathophysiology of the disease as well as the advances made in the speed and precision of laboratory diagnostic methods, an important development has occurred in the diagnosis of HIT.
similar resources
Heparin-induced thrombocytopenia.
Heparin-induced thrombocytopenia (HIT) is an immune complication of heparin therapy caused by antibodies to complexes of platelet factor 4 (PF4) and heparin. Pathogenic antibodies to PF4/heparin bind and activate cellular FcγRIIA on platelets and monocytes to propagate a hypercoagulable state culminating in life-threatening thrombosis. It is now recognized that anti-PF4/heparin antibodies devel...
full textHeparin-induced Thrombocytopenia
Nebojša M. Antonijević1, Nebojša Radovanović1, Slobodan Obradović2, Dragica Vučelić6, Bojan Stojanović1, Danijela Miković4, Mirjana Kovač4, Tina Kočica1, Svetlana Tadić4, Irina Antonijević4, Snežana Drašković4, Valentina Djordjević5, Branko Čalija6, Jovan Peruničić1, Zorana Vasiljević1 1 Institute of Cardiovascular Diseases, Clinical Centre of Serbia, Belgrade, Serbia; 2 Clinic of Emergency Med...
full textHeparin-induced thrombocytopenia.
Each year, 25% of all hospitalized patients are affected by venous thromboembolism, a disease comprising deep vein thrombosis and pulmonary embolism, that is responsible for up to 10% of all inpatient deaths (Alikhan, Peters, Wilmott, Cohen, 2004). Used in both the treatment and the prevention of venous thromboembolism, heparin is administered to more than 12 million patients each year in the U...
full textHeparin-Induced Thrombocytopenia
1 Shindo Y, Sato S, Maruyama E, et al. Health-care-associated pneumonia among hospitalized patients in a Japanese community hospital. Chest 2009; 135:633–640 2 Teramoto S, Yamamoto H, Yamaguchi Y, et al. Lower respiratory tract infection outcomes are predicted better by an age 80 years than by CURB-65. Eur Respir J 2008; 31:477–478 3 Teramoto S, Fukuchi Y, Sasaki H, et al. High incidence of asp...
full textMy Resources
Journal title
volume 16 issue 2
pages 133- 148
publication date 2019-07
By following a journal you will be notified via email when a new issue of this journal is published.
No Keywords
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023